ClinicalTrials.gg
WithdrawnNCT06789432Updated Oct 7, 2026

Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population

A Phase 4 interventional study of Atorvastatin 10 mg and ezetimibe 10 mg and Atorvastatin 20 mg in Hyperlipidemia (E.G., Hypercholesterolemia), sponsored by Dr. Md. Alimur Reza. Withdrawn at 1 site in Bangladesh. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Primary conditionHypercholesterolemiaRegistry: HyperlipidemiasReclassifiedWhy we changed it
Registry
Hyperlipidemias — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypercholesterolemia
Why
  1. The study's listed conditions name Hypercholesterolemia, a narrower term within Hyperlipidemias.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Dr. Md. Alimur Reza · Phase 4, Interventional, and Treatment

Why this study was withdrawn
Withdrawn by the sponsor before any participant was enrolled. Protocol-specified screening and randomization were not initiated at the study site. Not related to participant safety.
Updated Oct 7, 2026Now WithdrawnEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.

Enrollment
75th of 75
0 · median 148
Started
2025
the only one that year
Phase 4
28 of 77
1 open now
Registered
76th of 77
by date

Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 75th largest by enrollment of the 75 interventional ones that give a count, is the only one that started in 2025, is one of 28 in phase 4, and was the 76th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies testing atorvastatin in Hypercholesterolemia, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the efficacy and safety of a fixed-dose combination of atorvastatin (10 mg) and ezetimibe (10 mg) compared to atorvastatin (20 mg) monotherapy in the Bangladeshi population.

Researchers will compare atorvastatin (10 mg) and ezetimibe (10 mg) to atorvastatin (20 mg) monotherapy to see if atorvastatin (10 mg) and ezetimibe (10 mg) FDC works to treat dyslipidemia.

Participants will:

  • Take a fixed-dose combination of atorvastatin (10 mg) and ezetimibe (10 mg) compared to atorvastatin (20 mg) monotherapy for 3 months
  • Follow-up visits at 6 weeks and 12 weeks for checkups and tests
03

Conditions studied

  • Hyperlipidemia (E.G., Hypercholesterolemia)

Browse trials for

Keywords

  • increased LDL-C level
  • Hyperlipidemia
  • Atorvastatin (10 mg) and Ezetimibe (10 mg)
04

In context

Hypercholesterolemia Reclassified

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Lead sponsor

Dr. Md. Alimur Reza is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Compared within Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hyperlipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged >18 years.
  • Patients with a confirmed diagnosis of elevated LDL-C levels necessitating medical management.
  • Patients in the low to moderate cardiovascular disease (CVD) risk category according to ESC guidelines (2019)

    • Low-risk: Increased LDL-C level without any co-morbidities
    • Moderate-risk: Young patients (T1DM \<35 years; T2DM \<50 years) with DM duration \<10 years, without other risk factors.

Exclusion criteria

Exclusion Criteria:

  • History of to any study drugs.
  • hepatic impairment (, AST level > 2xULN) and/or renal impairment (Serum creatinine level ≥2xULN).
  • Patients with virus (HBV) or virus (HCV) with cirrhosis, end-stage liver disease, cancer, psychiatric instability, + status, intestinal malabsorption.
  • Pregnant or lactating females.
  • The presence of a condition that, in the opinion of the investigator, would place the subject at increased risk from study participation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Atorvastatin 10 mg and ezetimibe 10 mg

  • Experimental
    Arm 2

    Drug: Atorvastatin 20 mg

Interventions

  • DrugAtorvastatin 10 mg and ezetimibe 10 mg

    Drug page: Atorvastatin

    Atorvastatin/Ezetimibe 10/10mg once daily

  • Atorvastatin (20 mg) Monotherapy once daily

07

What researchers measure

Primary outcomes

  1. Mean change in LDL-C from baseline

    Compare the mean change in LDL-C (mg/dL) from baseline to week 12 in both groups.

    Time frame: Baseline to Week 12

  2. Percentage of patients withdrawn from the study

    Compare the percentage of patients withdrawn from the study due to adverse events in two groups.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Achievement of target levels of LDL-C

    Compare the frequency of achieving the target levels of LDL-C in both groups after 12 weeks

    Time frame: Baseline to Week 12

  2. Mean changes in total cholesterol (TC), HDL-C and TG

    Compare the mean changes in total cholesterol (TC), HDL-C and TG from baseline to week 12 in both arms.

    Time frame: Baseline to Week 12

  3. Frequency of myopathy

    Compare the frequency of myopathy after 12 weeks between two arms

    Time frame: Baseline to Week 12

  4. Frequency of AEs & SAEs

    Compare the frequency of AEs \& SAEs between two arms

    Time frame: Baseline to Week 12

  5. Changes in SGPT Levels in Both Arms

    Compare the change in SGPT (U/L) levels in both arms.

    Time frame: Baseline to Week 12

  6. Changes in Serum Creatinine Levels in Both Arms

    Compare the changes in SGPT (U/L) levels in both arms.

    Time frame: Baseline to Week 12

  7. Changes in creatine phosphokinase (CPK) level in Both Arms

    Compare the changes in creatine phosphokinase (CPK) level in Both Arms

    Time frame: Baseline to Week 12

08

Study locations

1 site
  • Popular Medical College & Hospital
    Dhaka, Dhaka Division, Bangladesh
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Oct 2025, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2025
First posted
Jan 23, 2025
StartActual
Feb 1, 2025
Primary completionEst.
Oct 2025
CompletionEst.
Dec 2025
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Withdrawn Withdrawn by the sponsor before any participant was enrolled. Protocol-specified screening and randomization were not initiated at the study site. Not related to participant safety.
changed Oct 7, 2026
Enrollment
500 (estimated)→0 (actual)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Recruiting→Withdrawn
    Why stopped Withdrawn by the sponsor before any participant was enrolled. Protocol-specified screening and randomization were not initiated at the study site. Not related to participant safety.
    Enrollment 500 (estimated)→0 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06789432
Lead sponsor
Dr. Md. Alimur Reza
Responsible party
Dr. Md. Alimur Reza (Epidemiologist, Beximco Pharmaceuticals Ltd.) — Sponsor-investigator
First posted
Jan 23, 2025
Start date
Feb 1, 2025
Primary completion
Oct 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Oct 7, 2026

Study contacts

Prof. Abdullah Al Shafi Majumder, MD, FACC, FRCP (E), FRCP (G)
principal investigator · Professor, Dept. of Cardiology, Popular Medical College, Dhaka.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion